ImmuPharma

Immupharma has filed a PCT application for its P140 approach to identify and treat patients with the so-called type-M immune profile. The application builds on a UK patent (priority Aug/Sep 2025) and includes additional experimental data generated during the 12-month priority period. The international phase includes search and publication and enables the pursuit of national/regional patent rights in selected markets. The company names P140 as a central value driver and aims to conclude a commercial agreement in 2026. » Więcej na de.investing.com

ImmuPharma has chosen Kymos Deutschland/Prolytic through a competitive tender as the bioanalytical contract research partner for the Kapiglucagon program. Kymos will develop and validate regulated bioanalytical methods and analyse samples from nonclinical and phase 1 studies. Kapiglucagon is a glucagon prodrug intended for type 1 diabetes applications, aiming to improve solubility and formulation stability for dual-hormone artificial pancreas systems. The program is supported by recently awarded funding; Thermo Fisher is the CMC partner and Bachem is supplying the API, and a US regulatory pathway via 505(b)(2) is being explored. » Więcej na de.investing.com

ImmuPharma has initiated IND‑preparatory activities for Kapiglucagon, a glucagon prodrug for treating type 1 diabetes, and has engaged tranScrip Limited to prepare a regulatory strategy and a pre‑IND briefing for the FDA. The company is considering a 505(b)(2) approval pathway in the US, which could allow use of existing data on native glucagon. Kapiglucagon aims to address issues with native glucagon by providing improved solubility and formulation stability and could also be used in artificial pancreas systems. After the pre‑IND meeting, ImmuPharma plans to submit an IND and start first human studies; the program is supported by a recently approved financing initiative. » Więcej na de.investing.com